2026-05-12 14:15:09
Latest Post
The New India Assurance Company Ltd consolidated Q4FY26 PAT higher at Rs. 564.16 crores
Abbott India Ltd Q4FY26 net profit at Rs. 394.93 crores
GE Power India Ltd Q4 FY2026 consolidated PAT at Rs. 113.21 crores
JB Chemicals and Pharmaceuticals Ltd consolidated Q4 FY26 profit drops to Rs. 101.37 crores
SPR Auto Technologies Ltd Q4FY26 consolidated profit up at Rs. 156.3 crores
Stock Report
CORONA Remedies Ltd reports consolidated PAT of Rs. 45.33 crore in Q4FY26
Posted On : 2026-05-12 10:46:17( TIMEZONE : IST )
CORONA Remedies Limited has reported Consolidated financial results for the period ended March 31, 2026.
Financial Results (Q4 FY2026) - QoQ Comparison
The company has reported total income of Rs. 357.20 crores during the period ended March 31, 2026 as compared to Rs. 344.66 crores during the period ended December 31, 2025.
The company has posted net profit / (loss) of Rs. 45.33 crores for the period ended March 31, 2026 as against net profit / (loss) of Rs. 41.27 crores for the period ended December 31, 2025.
The company has reported EPS of Rs. 7.41 for the period ended March 31, 2026 as compared to Rs. 6.75 for the period ended December 31, 2025.
| Financials | Q4 FY2026 | Q3 FY2026 | % Change |
| Total Income | ₹ 357.20 crs | ₹344.66 crs |  3.64% |
| Net Profit | ₹ 45.33 crs | ₹41.27 crs | 9.84% |
| EPS | ₹7.41 | ₹6.75 | 9.78% |
Financial Results (Q4 FY2026) - YoY Comparison
The company has reported total income of Rs. 357.20 crores during the period ended March 31, 2026 as compared to Rs.295.11 crores during the period ended March 31, 2025.
The company has posted net profit / (loss) of Rs. 45.33 crores for the period ended March 31, 2026 as against net profit / (loss) of Rs.31.55 crores for the period ended March 31, 2025.
The company has reported EPS of Rs.7.41 for the period ended March 31, 2026 as compared to Rs.5.16 for the period ended March 31, 2025.
| Financials | Q4 FY2026 | Q4 FY2025 | % Change |
| Total Income | ₹ 357.20 crs | ₹295.11 crs | 21.04% |
| Net Profit | ₹ 45.33 crs | ₹31.55 crs | 43.68% |
| EPS | ₹7.41 | ₹5.16 | 43.60% |
Financial Results (Year Ended FY2026) - YoY Comparison
The company has reported total income of Rs.1413.83 crores during the Financial Year ended March 31, 2026 as compared to Rs.1202.35 crores during the Financial Year ended March 31, 2025.
The company has posted net profit / (loss) of Rs.185.12 crores for the Financial Year ended March 31, 2026 as against net profit / (loss) of Rs.149.43 crores for the Financial Year ended March 31, 2025.
The company has reported EPS of Rs.30.27 for the Financial Year ended March 31, 2026 as compared to Rs.24.43 for the Financial Year ended March 31, 2025.
| Financials | Year Ended FY2026 | Year Ended FY2025 | % Change |
| Total Income | ₹1413.83 crs | ₹1202.35 crs | 17.59% |
| Net Profit | ₹185.12 crs | ₹149.43 crs | 23.88% |
| EPS | ₹30.27 | ₹24.43 | 23.91% |
Shares of CORONA Remedies Limited was last trading in BSE at Rs. 1753.20 as compared to the previous close of Rs. 1712.15. The total number of shares traded during the day was 2532 in over 472 trades.
The stock hit an intraday high of Rs. 1804.90 and intraday low of 1712.00. The net turnover during the day was Rs. 4465509.00.
